Technical Analysis for NCNA - NuCana plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.84 | -4.00% | -0.16 |
Earnings due: May 15
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -4.00% | |
| NR7-2 | Range Contraction | -4.00% | |
| Narrow Range Bar | Range Contraction | -4.00% | |
| Inside Day | Range Contraction | -4.00% | |
| Wide Bands | Range Expansion | -4.00% | |
| Oversold Stochastic | Weakness | -4.00% | |
| Slingshot Bearish | Bearish Swing Setup | -3.76% |
| Alert | Time |
|---|---|
| Down 5% | about 15 hours ago |
| Fell Below Previous Day's Low | about 16 hours ago |
| Possible NR7 | about 17 hours ago |
| Possible Inside Day | about 17 hours ago |
| Down 3% | about 18 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/15/2024
NuCana plc Description
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Health Sciences Treatment Of Cancer Drug Discovery Cancer Cell Solid Tumor Cancers Prodrugs Gemcitabine Organofluorides
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 23.6925 |
| 52 Week Low | 3.4 |
| Average Volume | 88,659 |
| 200-Day Moving Average | 11.59 |
| 50-Day Moving Average | 7.11 |
| 20-Day Moving Average | 5.26 |
| 10-Day Moving Average | 4.32 |
| Average True Range | 0.77 |
| RSI (14) | 27.01 |
| ADX | 39.87 |
| +DI | 11.67 |
| -DI | 28.54 |
| Chandelier Exit (Long, 3 ATRs) | 5.76 |
| Chandelier Exit (Short, 3 ATRs) | 5.72 |
| Upper Bollinger Bands | 7.54 |
| Lower Bollinger Band | 2.97 |
| Percent B (%b) | 0.19 |
| BandWidth | 86.92 |
| MACD Line | -1.01 |
| MACD Signal Line | -0.91 |
| MACD Histogram | -0.0944 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.35 | ||||
| Resistance 3 (R3) | 4.38 | 4.23 | 4.27 | ||
| Resistance 2 (R2) | 4.23 | 4.10 | 4.22 | 4.24 | |
| Resistance 1 (R1) | 4.04 | 4.02 | 3.97 | 4.01 | 4.21 |
| Pivot Point | 3.89 | 3.89 | 3.86 | 3.88 | 3.89 |
| Support 1 (S1) | 3.70 | 3.76 | 3.63 | 3.67 | 3.47 |
| Support 2 (S2) | 3.55 | 3.68 | 3.54 | 3.44 | |
| Support 3 (S3) | 3.36 | 3.55 | 3.42 | ||
| Support 4 (S4) | 3.33 |
